CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

Abstract Background Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the...

Full description

Bibliographic Details
Main Authors: Wilson Eduardo Furlan Matos Alves, Murilo Bonatelli, Rozany Dufloth, Lígia Maria Kerr, Guilherme Freire Angotti Carrara, Ricardo Filipe Alves da Costa, Cristovam Scapulatempo-Neto, Daniel Tiezzi, René Aloísio da Costa Vieira, Céline Pinheiro
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Cancer
Subjects:
Breast cancer
CAIX
Glycolytic metabolism
Immunohistochemistry
Neoadjuvant chemotherapy
Pathological complete response
Online Access:https://doi.org/10.1186/s12885-019-6353-2

Internet

https://doi.org/10.1186/s12885-019-6353-2

Similar Items